FibroGen Reports Q4 2022 Financial Results with Revenue Growth
US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global...
Fineline Cube
China Issues New Ethical Review Measures for Life Sciences and Medical Research
The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration...
Bayer Reports 2022 Sales Growth, Highlights New Drug Performances
Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...
China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access
The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1,...
China’s State Council Unveils Plan for TCM Revitalization and Development
The State Council has released the “Traditional Chinese Medicine (TCM) Revitalization and Development Major Projects...
Topchoice Medical to Acquire 19% Stake in Heren Health for $72.2M
China-based Topchoice Medical Investment Corp., (SHA: 600763) a leading medical service group, is set to...
Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations
China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B...
RinuaGene Raises $14.4M in Pre-Series A+ for mRNA Drug Development
RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100...
Junshi Biosciences Reports 2022 Preliminary Earnings with Revenue Decline
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...
Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...
Suzhou Porton Biologics Partners with CorrGene for Cell and Gene Therapy
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has announced a strategic...
Sanofi’s Sarclisa Approved for Import in Shenzhen via Greater Bay Area Scheme
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced import approval in Shenzhen via the Greater...
Innovent Biologics Begins Phase I Trial for IBI333 in Neovascular AMD
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first subject dosing in a Phase...
Hybio’s COVID-19 Nasal Spray HY3000 Gets FDA Clinical Trial Approval
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving tacit clinical trial approval from...
Junshi Biosciences’ PCSK9 Inhibitor Ongericimab Meets Phase III Endpoints
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that two randomized, double-blind, placebo-controlled, multi-center...
Oricell Therapeutics Closes $45M Series B1 Round for Cellular Immunotherapy
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a...
CStone’s PD-L1 Inhibitor Sugemalimab Accepted for Review in Gastric Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
Immorna Closes Series A+ and A++ Rounds Near $100M for mRNA Development
Immorna (Hangzhou) Biotechnology Co., Ltd has announced the successful closure of Series A+ and A++...
Sanofi’s VaxigripTetra Approved for Pediatric Influenza Vaccination in China
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced receiving market approval from the National Medical...